{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005903","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.922032+00:00","generated_at":"2026-05-31T08:39:17.152112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)","bullets":["Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.","Net loss for Q2 2024 was $(494,300) vs $(902,108) in Q2 2023, a 45% improvement.","YTD revenue $16,844,113, up 61% from $10,454,918; YTD net loss $(1,778,101) improved 32%.","Sequential Q2 sales grew 23% over Q1 2024 sales of $7,541,046.","Shareholders' equity $23,489,865, up 11% from Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005903","json":"https://secwatch.observer/filing/0001683168-24-005903.json","markdown":"https://secwatch.observer/filing/0001683168-24-005903.md","text":"https://secwatch.observer/filing/0001683168-24-005903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/0001683168-24-005903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:39:17.152112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}